The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs

Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis

(2021) Chun-xing Li et al.   PLoS One

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

(2021) Dario Giugliano et al.   Cardiovascular Diabetology

The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials

(2021) Donna Shu-Han Lin et al.   DIABETOLOGIA

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

(2021) Emily Brown et al.   LANCET

Evolving Concepts of Type 2 Diabetes Management

(2021) Layla A. Abushamat et al.   MEDICAL CLINICS OF NORTH AMERICA

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off

(2021) Dario Giugliano et al.   Cardiovascular Diabetology

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

(2021) Dario Giugliano et al.   Cardiovascular Diabetology

Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression

(2021) Maria Ida Maiorino et al.   Cardiovascular Diabetology

Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis

(2021) Yuki Kawai et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials

(2020) Dario Giugliano et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

(2019) Yue Fei et al.   Cardiovascular Diabetology

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Diabetes and Cardiovascular Disease: an Update

(2019) Rajaa Almourani et al.   Current Diabetes Reports

Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017

(2018) Thomas R. Einarson et al.   Cardiovascular Diabetology

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

(2018) Sandeep R. Das et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ranking treatments in frequentist network meta-analysis works without resampling methods

(2015) Gerta Rücker et al.   BMC Medical Research Methodology

Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people

(2015) Anoop Dinesh Shah et al.   Lancet Diabetes & Endocrinology

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus

(2012) Harshal R. Patil et al.   AMERICAN JOURNAL OF CARDIOLOGY

Evidence Synthesis for Decision Making 2

(2012) Sofia Dias et al.   MEDICAL DECISION MAKING